Myomo, Inc. (MYO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Myomo, Inc. (MYO) Healthcare & Pipeline Overview

Myomo, Inc. is a wearable medical robotics company specializing in myoelectric orthotics for individuals with neuromuscular disorders. Its MyoPro device supports weakened upper limbs, enhancing daily functional activities for patients affected by conditions such as stroke and traumatic brain injury, positioning it within the specialized medical device sector.

What Is the Investment Thesis for MYO?

Myomo, Inc. presents an investment thesis centered on its specialized MyoPro myoelectric orthosis, addressing a significant unmet need in neuromuscular rehabilitation. The company's gross margin of 66.0% indicates strong product-level profitability, despite an overall profit margin of -36.7% and a negative ROE of -98.5%, suggesting ongoing investment in growth and operational scale-up. The MyoPro's ability to improve functional activities for individuals with conditions like stroke and brachial plexus injury positions Myomo in a growing market for assistive medical devices. Key growth catalysts include expanding insurance coverage for myoelectric orthotics, increasing adoption within the Veterans Health Administration, and potential market penetration into new geographic regions or additional neuromuscular indications. The company's focus on a high-value, clinically proven device provides a foundation for future revenue growth, contingent on scaling its sales and distribution channels effectively. However, a high debt-to-equity ratio of 210.65 and negative profitability highlight the importance of achieving operational efficiency and positive cash flow generation to sustain long-term value creation.

Based on FMP financials and quantitative analysis

MYO Key Highlights

Market capitalization stands at $52.9M, reflecting its position as a small-cap company in the medical device sector.

• Gross margin of 66.0% demonstrates strong product-level profitability, indicating efficient cost management relative to revenue from device sales.
• Profit margin of -36.7% indicates the company is currently operating at a net loss, likely due to ongoing investments in research, development, and market expansion.
• Return on Equity (ROE) of -98.5% highlights significant unprofitability relative to shareholder equity, consistent with its negative profit margin.
• Debt-to-Equity (D/E) ratio of 210.65 suggests a substantial reliance on debt financing compared to equity, which could imply higher financial risk.

Who Are MYO's Competitors?

MYO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are MYO's Key Strengths?

Proprietary MyoPro technology addresses a specific, high-need market for upper limb rehabilitation.

• Strong gross margin of 66.0% indicates efficient manufacturing and pricing power for its specialized device.
• Established sales channels through the Veterans Health Administration, O&P providers, and rehabilitation hospitals.
• Focus on improving functional activities of daily living for patients, leading to strong clinical value proposition.

What Are MYO's Weaknesses?

Negative profit margin (-36.7%) and ROE (-98.5%) indicate current unprofitability and reliance on external funding.

• High debt-to-equity ratio (210.65) suggests significant financial leverage and potential sensitivity to interest rate changes.
• Relatively small market capitalization ($52.9M) may limit access to capital compared to larger competitors.
• Limited geographic reach, primarily operating within the United States.

What Could Drive MYO Stock Higher?

MYO catalyst: **Upcoming:** Announcement of expanded insurance coverage from a major private payer for MyoPro, potentially broadening patient access and sales volume.

• **Ongoing:** Continued positive clinical outcomes data from MyoPro users, reinforcing its efficacy and supporting broader adoption by healthcare providers and institutions.
• **Upcoming:** Introduction of a new MyoPro model or an update with enhanced features, potentially stimulating demand and expanding the product's addressable market.
• **Ongoing:** Increased procurement and utilization of MyoPro devices by the Veterans Health Administration, driven by successful patient outcomes and awareness campaigns.
• **Upcoming:** Entry into a new international market, following successful regulatory approvals and establishment of a distribution network, diversifying revenue streams.

What Are the Key Risks for MYO?

Financial-distress signal — its Altman Z-Score of -3.41 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• **Potential:** Dependence on third-party reimbursement policies, where changes in coverage or payment rates by private insurers or government programs could negatively impact sales and profitability.
• **Ongoing:** Significant competition from other medical device companies offering alternative rehabilitation solutions or traditional orthotics, potentially limiting market share and pricing power.
• **Potential:** Inability to secure additional capital to fund ongoing operations and growth initiatives, given the current negative profit margin and high debt-to-equity ratio.
• **Ongoing:** Regulatory hurdles and compliance costs associated with medical device development and sales, including potential delays in obtaining necessary clearances for new products or market expansions.
• **Potential:** Product liability claims or recalls, which could result from device malfunctions or adverse patient outcomes, leading to significant financial and reputational damage.

What Are the Growth Opportunities for MYO?

• **Expanding Insurance Coverage and Reimbursement:** The market for MyoPro is significantly influenced by insurance coverage. As clinical evidence demonstrating the device's efficacy and cost-effectiveness accumulates, there is an ongoing opportunity to expand coverage with private insurers and government programs beyond existing approvals. Successful advocacy for broader reimbursement policies could unlock a larger patient population, potentially increasing market penetration across the United States. This expansion could significantly impact revenue growth over the next 3-5 years, as more patients gain access to the technology.
• **Penetration within the Veterans Health Administration (VHA):** Myomo already sells to the VHA, which represents a substantial and consistent customer base for medical devices. There is a significant opportunity to deepen this relationship and increase the volume of MyoPro devices prescribed and dispensed through VHA facilities. Enhanced educational programs for VHA clinicians and therapists, coupled with streamlined procurement processes, could drive higher adoption rates. This channel offers a stable growth trajectory, potentially contributing to consistent revenue streams over the medium term (2-4 years).
• **Geographic Expansion Beyond the United States:** While currently focused on the U.S. market, Myomo has the potential to expand internationally. Neuromuscular disorders are global health challenges, and markets in Europe, Asia, and other developed regions represent untapped opportunities. Navigating international regulatory frameworks and establishing distribution networks would be complex but could dramatically increase the total addressable market for MyoPro. This long-term growth opportunity (5+ years) could significantly diversify Myomo's revenue base and reduce reliance on a single market.
• **Development of Next-Generation Devices and Indications:** Continuous research and development into new features, improved ergonomics, or even entirely new myoelectric devices could open new market segments. Furthermore, exploring the application of MyoPro technology to a broader range of neuromuscular conditions or even pediatric populations could expand its indications for use. Investing in R&D to enhance product capabilities and broaden therapeutic applications ensures Myomo remains at the forefront of wearable medical robotics, securing future growth avenues over a 3-7 year horizon.
• **Increased Adoption through Orthotics and Prosthetics (O&P) Providers:** O&P providers are critical touchpoints for patients requiring custom orthoses. Strengthening relationships with these providers through training, support, and marketing initiatives can drive increased MyoPro prescriptions. Educating O&P professionals on the clinical benefits and fitting procedures of MyoPro can lead to greater confidence and willingness to recommend the device. This channel offers a direct route to patients and represents a consistent growth opportunity over the next 2-5 years by leveraging existing healthcare infrastructure.

What Threats Does MYO Face?

• Intense competition from other medical device companies developing assistive technologies or traditional orthotics.
• Regulatory changes or delays in approvals for new products or expanded indications could impact market entry.
• Reliance on third-party reimbursement policies, which can be subject to change and impact sales volumes.
• Technological obsolescence if competitors introduce more advanced or cost-effective solutions.

What Are MYO's Competitive Advantages?

• **Proprietary Myoelectric Technology:** Myomo possesses specialized myoelectric control technology embedded in its MyoPro device, which allows for intuitive and functional movement based on residual muscle signals.
• **FDA Clearance and Clinical Validation:** The MyoPro has undergone rigorous testing and received necessary regulatory clearances, providing a significant barrier to entry for new competitors requiring similar extensive validation.
• **Established Distribution Channels:** Relationships with the Veterans Health Administration, orthotics and prosthetics providers, and rehabilitation hospitals represent established channels that are difficult for new entrants to replicate quickly.
• **Specialized Patient Population Focus:** By focusing on specific neuromuscular disorders, Myomo has developed deep expertise and tailored solutions for a niche market, building trust and brand recognition within this community.

What Does MYO Do?

Myomo, Inc., established in 2004 and headquartered in Boston, Massachusetts, operates as a pioneering wearable medical robotics company focused on enhancing the lives of individuals with neuromuscular disorders. The company designs, develops, and produces advanced myoelectric orthotics, with its flagship product being the MyoPro. This innovative device functions as a myoelectric-controlled upper limb brace or orthosis, engineered to provide crucial support for a patient's weak or paralyzed arm. The primary objective of the MyoPro is to enable and significantly improve functional activities of daily living for its users. Myomo's technology addresses a critical need for patients suffering from a range of debilitating neuromuscular conditions, including but not limited to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and various other neurological disorders that impair upper limb mobility and strength. The company's product development is rooted in the understanding that restoring even partial function can dramatically impact a patient's independence and quality of life. Myomo employs a multi-channel distribution strategy to reach its target demographic. Its products are sold directly to orthotics and prosthetics providers, which are key intermediaries in fitting and customizing such devices for patients. Additionally, Myomo engages with the Veterans Health Administration, recognizing the significant population of veterans who may benefit from its technology due to service-related injuries or other conditions. Rehabilitation hospitals also represent a vital sales channel, integrating MyoPro into comprehensive therapy programs. Furthermore, the company leverages a network of distributors to broaden its market penetration across the United States. Myomo's evolution since its incorporation reflects a commitment to innovation in the medical device sector, specifically targeting the niche of assistive robotics for neurological rehabilitation.

What Products and Services Does MYO Offer?

• Designs and develops myoelectric orthotics for individuals with neuromuscular disorders.
• Produces the MyoPro, a myoelectric-controlled upper limb brace.
• The MyoPro supports weak or paralyzed arms to improve daily functional activities.
• Aids adults and adolescents suffering from conditions like stroke, brachial plexus injury, and traumatic brain injury.
• Sells products to orthotics and prosthetics providers.
• Distributes devices to the Veterans Health Administration.
• Supplies rehabilitation hospitals with its MyoPro system.
• Utilizes a network of distributors to reach patients across the United States.

How Does MYO Make Money?

• Develops and manufactures advanced medical devices (myoelectric orthotics).
• Generates revenue through direct sales of its MyoPro device to healthcare providers and institutions.
• Partners with orthotics and prosthetics providers who fit and dispense the MyoPro to patients.
• Secures contracts and sales with government entities like the Veterans Health Administration.
• Leverages a distributor network to expand market reach and sales volume.

What Industry Does MYO Operate In?

Myomo, Inc. operates within the specialized segment of the broader Healthcare sector, specifically the Medical Devices industry. This industry is characterized by continuous innovation, stringent regulatory oversight, and a focus on improving patient outcomes through advanced technology. The market for assistive and rehabilitative medical devices, particularly those employing robotics and myoelectric control, is experiencing growth driven by an aging global population, increasing prevalence of neurological disorders, and advancements in bio-sensing technologies. Myomo's MyoPro device positions it within the niche of upper limb orthotics for neuromuscular conditions, a segment where personalized and high-functionality solutions are highly valued. The competitive landscape includes both traditional orthotic manufacturers and emerging robotic rehabilitation companies. Myomo differentiates itself through its myoelectric control technology, which allows for intuitive patient interaction and functional improvement. The company navigates a market influenced by healthcare reimbursement policies and the need for clinical evidence to support device efficacy and adoption.

Who Are MYO's Key Customers?

• Orthotics and prosthetics (O&P) providers who fit and dispense custom medical devices.
• The Veterans Health Administration (VHA), serving military veterans with various medical needs.
• Rehabilitation hospitals and clinics focused on physical and occupational therapy.
• Adults and adolescents diagnosed with neuromuscular conditions causing upper limb weakness or paralysis.
• Patients recovering from conditions such as stroke, brachial plexus injury, traumatic brain injury, and spinal cord injury.

Over the past six months, Myomo, Inc. insiders filed 30 SEC Form 4 transactions — 16 sales and 14 purchases. On net that is roughly 583K shares acquired (about $262K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Myomo, Inc.

Revenue for Myomo, Inc. came in at $11.7M during Q2 FY2026, a 15.7% improvement versus the preceding quarter. The company recorded a net loss of $4.0M, with diluted EPS of $-0.09. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MYO averaged $-0.09 in diluted EPS.

MYO Valuation & Market Position

With a $52.9M market cap, Myomo, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $1.10 to $5.75, with a consensus of $3.45. At the current price of $1.37, that implies approximately 152% upside potential. Relative to its peer group, MYO's quantitative score of 23/100 is below the peer average of 49/100.

Key Financial Metrics

Return on assets is -41.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.2%, the inverse of the P/E and a quick read on earnings relative to price.

Myomo, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.41 places it in the distress zone, a signal of elevated financial risk.

Myomo, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 13.0% above estimates on average.

Company Profile

Myomo, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Burlington, US. The company is led by CEO Paul R. Gudonis. MYO has traded publicly since 2017.

MYO Financials

MYO Latest News

MYO Analyst Consensus

MYO MoonshotScore

Myomo, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources